Dalfampridine in Egyptian Patients With Multiple Sclerosis
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as
fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and
improves impaired axonal conduction by selectively blocking potassium channels. Moreover,
further studies investigated the possible beneficial effect of dalfampridine on cognitive
functions and fatigue.
The main objective of this study is to investigate the effect of dalfampridine on gait
impairment, cognitive functions and fatigue in a sample of Egyptian patients with multiple
sclerosis.